Alpine Immune Sciences Inc buy Quitte
Start price
15.03.18
/
50%
€8.17
Target price
23.01.19
€12.45
Performance (%)
-40.07%
End price
23.01.19
€4.90
Summary
This prediction ended on 23.01.19 with a price of €4.90. The BUY prediction by Quitte for Alpine Immune Sciences Inc performed very badly with a performance of -40.07%. Quitte has 50% into this predictionAlpine Immune Sciences is a clinical-stage biotechnology company focused on developing novel therapies that modulate the immune system to treat cancer, autoimmune, and inflammatory diseases. The company's proprietary platform technology, called "Variant Ig Domain" (vIgD), enables the design and development of unique protein therapeutics that can target specific immune cells and pathways. Alpine's lead product candidate, ALPN-202, is a dual ICOS/CD28 antagonist for the treatment of autoimmune and inflammatory diseases, and the company has several other product candidates in preclinical development. Alpine Immune Sciences is listed on the NASDAQ stock exchange under the ticker symbol "ALPN".
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alpine Immune Sciences Inc | - | - | - | - |
| iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
| iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
| iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
| iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by Quitte for this prediction
In the thread Alpine Immune Sciences Inc diskutieren
auf zu alpinen Gipfeln
(Laufzeit überschritten)